Reviewed Preprint
v1 • January 16, 2025
Not revised

Reviewed Preprint
v2 • February 20, 2026
Revised by authors

Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancer

Yue Zhang[1], Hanbing Wang[1], Yutao Wei[2], Yunfeng Pan[1], Xueru Song[1], Jie Shao[1], Lixia Yu[1], Tao Shi[1] ✉, Yue Wang[1] ✉

[1]Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China • [2]Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China

For correspondence:
taoshi@smail.nju.edu.cn
wangyue2012nju@163.com

Competing interests: The authors declare that they have no conflict of interest.

Funding: See page 16

Reviewing editor: Richard Philip Grose, Queen Mary University of London, United Kingdom

eLife Assessment

Based on the perceived low efficacy of current therapies targeted to FGFR2 in gastric cancer (GC), the authors investigate an approach which combines SHP2 inhibition with existing FGFR2 inhibitors. The data were largely collected and analysed using **solid** and validated methodology. There is some **useful** data regarding combination therapy in a new clinical cohort, which supports previous studies that have reported the potential of targeting RTKs together with phosphatases.

https://doi.org/10.7554/eLife.104060.2.sa4

Abstract

Fibroblast growth factor receptor 2 (FGFR2) is an important member of receptor tyrosine kinase (RTK) family. FGFR2 amplification occurs at a high frequency in gastric cancer (GC) and has been proven to be closely associated with poor prognosis and insensitivity to chemotherapy or immunotherapy. Current FGFR2-targeted therapies have limited efficacy. Hence, how to enhance efficacy and reverse resistance are urgent problems clinically. Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) serves as the shared downstream mediator of all RTKs and a prominence immunosuppressive molecule. In this study, we identified FGFR2 amplification in 6.2% (10/161) of GC samples in our center. Then we showed that dual blocking SHP2 and FGFR2 enhanced the effects of FGFR2 inhibitor (FGFR2i) in FGFR2-amplified GC both *in vitro* and *in vivo* via suppressing RAS/ERK and PI3K/AKT pathways. We further showed that it overcame FGFR2i resistance by reversing the feedback activation mediated by other RTKs and continuously suppressing FGFR2-initiated downstream pathways. Notably, SHP2 blockade could suppress PD-1 expression and promoted IFN-γ secretion of $CD8^+$ T cells, enhancing the cytotoxic functions of T cells in tumor immune microenvironment. Overall, our findings suggest that dual blocking SHP2 and FGFR2 is a compelling rationale with both targeted treatment and immune regulation for FGFR2-amplified GC.

Funding information This work was funded by Grants from National Natural Science Foundation of China (82403862, 82403835), Jiangsu Provincial Natural Science Foundation Youth Project (BK20230151, BK20240247), Jiangsu Provincial Major Science and Technology Program (BG2024026), the Wu Jieping Medical Foundation Special Fund for Targeted Cancer Therapy (Youth Research Project) (320.6750.2023-11-30), Jiangsu Provincial Youth Science and Technology Talent Support Project (JSTJ-2025-715) and General Project of Nanjing Health Science and Technology Development Program (YKK24084).

Impact statement

Dual blocking SHP2 and FGFR2 can not only promote the targeted tumor-killing effects and overcome FGFR2 inhibitor resistance caused by feedback activation, but also activate T cell-mediated anti-tumor immunity by inhibiting PD-1 pathway in FGFR2-amplified GC.

Introduction

Gastric cancer (GC) ranks as the third leading cause of cancer death globally(Ajani et al., 2022; Smyth et al., 2020; Wei et al., 2020). Due to the absence of specific early signs, over 70% of GC patients are diagnosed at an advanced stage(Guan et al., 2023; Song et al., 2017). Concurrently, treatments for advanced GC predominantly include chemotherapy, targeted therapy, radiotherapy and immunotherapy. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab plus chemotherapy has been approved by Food and Drug Administration (FDA) as the standard first-line treatment for advanced GC(Janjigian et al., 2021; Smyth et al., 2020; Zhao et al., 2022). Meanwhile, the Cancer Genome Atlas (TCGA) has classified GC patients into four subtypes including Epstein Barr virus (EBV) type, Microsatellite Instability (MSI) type, Genomic stability (GS) type and chromosomal instability (CIN) type("Comprehensive molecular characterization of gastric adenocarcinoma," 2014). Among them, EBV and MSI types are more likely to benefit from immunotherapies, while CIN and GS types tend to be less responsive. Fortunately, the unique composition structure of CIN type provides potential anti-tumor targets. CIN type is in the majority, accounting for about 50%, with distinct aneuploidy and focal amplification of receptor tyrosine kinases (RTKs) as its molecular feature("Comprehensive molecular characterization of gastric adenocarcinoma," 2014). RTKs are common tumor-driven genes, including human epidermal growth factor receptor 2 (HER-2), fibroblast growth factor receptor 2 (FGFR2), epidermal growth factor receptor (EGFR) and so on(Du & Lovly, 2018; Paul & Hristova, 2019). The combination of anti-HER-2 antibody Trastuzumab and chemotherapy has been approved by FDA as the first-line treatment for HER-2 positive advanced GC(Kang, 2023; Smyth et al., 2020; Yang et al., 2020). In the meantime, other RTKs, especially FGFR2, have also displayed huge potential as anti-tumor targets.

FGFR2 is also a representative member of the RTK family. Several studies have documented that FGFR2 blockade can inhibit the occurrence and development of malignant tumors by regulating PI3K/AKT, RAS/ERK and JAK/STAT pathways(Babina & Turner, 2017; Gordon et al., 2022; Katoh & Nakagama, 2014). It's worth noting that FGFR2 amplification has been identified in up to 7.7% of advanced GC patients(Jogo et al., 2021), and is closely associated with poor prognosis and limited response to chemotherapy and immunotherapy(Ahn et al., 2016; Hur et al., 2020; Kim, Kim, Jang, et al., 2019; Koh et al., 2019). Currently, there've been several approaches for FGFR2 inhibition in FGFR2-amplified GC. For instance, Bemarituzumab (FPA144) is a specific anti-FGFR2b monoclonal antibody(Katoh et al., 2024), However, in a phase II clinical trial (NCT03694522), it has been demonstrated that Bemarituzumab monotherapy didn't statistically significantly improve progression-free survival (PFS) in FGFR2b-selected GC patients(Wainberg et al., 2022). Besides, small molecule inhibitors targeting FGFR2 are also primary methods for FGFR2-amplified GC treatment. AZD4547 is an FGFR-selective inhibitor targeting FGFR1-3, which has been widely used as an FGFR2 inhibitor in researches focusing on FGFR2-amplified tumors(Jang et al., 2017; Xie et al., 2013). In a previous phase II clinical trial (NCT01795768), AZD4547 achieved an overall response rate (ORR) of 33% in patients with previously treated advanced FGFR2-amplified gastroesophageal cancer, and a median PFS of responding patients of 6.6 months(Pearson et al., 2016). Based on its distinguished therapeutic effects, AZD4547 was granted by FDA as an orphan drug for GC. However, subgroup analysis indicated that robust single-agent response to AZD4547 was only observed in high-level FGFR2-amplified cancers in this trial(Pearson et al., 2016). And in another phase II clinical trial (NCT01457846), AZD4547 failed to significantly improve patients' PFS compared to paclitaxel (3.5 months vs 1.8 months, P=0.9581) as a second-line treatment for

advanced gastric adenocarcinoma(Van Cutsem et al., 2017). Given that inhibiting FGFR2 alone is often difficult to achieve ideal therapeutic effects, identifying suitable combinations is crucial to the treatment of FGFR2-amplified GC.

Although RTK targeted therapies have been proved to have certain anti-tumor therapeutic effects, drug resistance of RTK inhibitors remain a common problem. One of the main reasons for RTK inhibitors resistance is the activation of downstream signaling pathways mediated by bypass RTKs. Previous researches have revealed that the downstream pathway feedback upregulation caused by EGFR activation leaded to FGFR2 inhibitor resistance in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusion(Wu et al., 2022). Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) is the common downstream factor of RTKs including FGFR2, acting as a central node between FGFR2 and PI3K/AKT, RAS/ERK or JAK/STAT pathways(Chen et al., 2016; Sodir et al., 2023). As the shared molecule downstream of all RTKs, SHP2 inhibitor and its combination with RTK inhibitors were reported to be ideal strategies for treating a large class of RTK-driven cancers, including EGFR-amplified, KRAS-amplified, KRAS G12C-mutanted cancers and so on(Chen et al., 2016; Fedele et al., 2021; Wong et al., 2018). Therefore, we speculate that the combination of FGFR2 inhibitor and SHP2 inhibitor is likely to alleviate FGFR2 inhibitor resistance by inhibiting the feedback activation of bypass RTK pathways.

Meanwhile, SHP2 is also a significant downstream molecule of PD-1(Chen et al., 2016; Song et al., 2022). SHP2 has been proved to suppress T cell activation by inactivating TCR and CD28 signaling(Li et al., 2015), which are two costimulatory signals mediating T cell development and maturation(Ai et al., 2020; Liu et al., 2020). Numerous preclinical studies have revealed that SHP2 inhibition can inhibit tumors by enhancing anti-tumor immunity(Liu et al., 2017; Zhao et al., 2019). Accordingly, we suppose that simultaneously blocking FGFR2 and SHP2 has the potential to suppress tumor growth through both targeted intervention and immune activation.

Overall, we aim to explore the combined anti-tumor capacity and potential mechanisms of co-inhibiting FGFR2 and SHP2 in FGFR2-amplified GC, providing a “two-pronged” combination therapy mode with targeted and immune dual effects for GC patients with FGFR2 amplification.

Methods

Patient samples and next-generation sequencing

We collected gastroscopy biopsy or surgically collected specimens of 161 GC patients from January 2016 to August 2023 in Nanjing Drum Tower Hospital. Next-generation sequencing (NGS) and analysis were performed in OrigiMed (Shanghai, China) based on 450 YuanSu^{TM} gene panel. At least 50 ng DNA were extracted from Formalin fixed paraffin-embedded (FFPE) tumor tissues using QIAamp DNA FFPE Tissue Kit. Genes capture and sequencing were performed at a mean depth of 1000× by Illumina NextSeq 500 (San Diego, CA, USA). Gene alterations, including substitution, gene amplification, gene homozygous deletion, gene fusion and truncation were evaluated. Tumor mutation burden (TMB) was estimated by calculating somatic non-synonymous mutations per megabase in each patient. The study was carried out in compliance with the code of ethics of the World Medical Association (Declaration of Helsinki) and approved by the Ethics Committee of Nanjing Drum Tower Hospital (No. 2021-324-01).

Mice

Four to six-week-old female BALB/c nude mice were purchased from GemPharmatech Co. Ltd. Mice were kept in specific pathogen-free animal facilities at the Comprehensive Cancer Centre of Nanjing Drum Tower Hospital.

Cells

Human GC cell line KATOIII was donated from Nanjing University Chao Yan laboratory. Human GC cell lines SNU-16 (ATCC CRL-5974), MKN45 (KANGBAI CBP60488), NUGC4 (KANGBAI CBP60493), HGC27 (KANGBAI CBP60480) and SNU601 (KANGBAI CBP60507) were purchased from the Cell

Bank of the Chinese Academy of Sciences (Shanghai, China). All cells were cultured in Roswell Park Memorial Institute (RMPI) 1640 medium supplemented with 10% fetal calf serum (FBS) and 1% penicillin-streptomycin at 37°C with 5% CO_2. Primary GC cells were derived from ascites of a FGFR2-amplified GC patient who was resistant to FGFR2 inhibitors. Primary human peripheral blood mononuclear cells (PBMCs) were separated from human peripheral blood donated by 2 healthy people by Ficoll (TBD, LTS1077) and induced by 80 IU/ml IL-2 (Pepro Tech, 200-02). Human sample used in this study obtained the patients' consent and the approval of the Ethics Committee of Nanjing Drum Tower Hospital (No. 2021-324-01).

CCK-8 assay

Cell Counting Kit-8 (CCK-8) (Vazyme, A311-01/02) assay was used to evaluate the effects of AZD4547 (Selleck, S2801), SHP099 (MedChemExpress, HY-100388) and combination administration on cancer cell proliferation. 3000 GC cells were seeded in 96-well plates with 100 μl of 10% FBS 1640 medium, and treated with SHP099, AZD4547 or combination therapy on the 2rd day. After 4 days incubation, 10 μl CCK-8 was added into each well and incubated for 2h. Asorbance was measured at 450 nm with microplate reader. Cell viability=[(OD_Drug-OD_Blank)/(OD_Control-OD_Blank)]×100%.

Cell apoptosis analysis

Annexin V-FITC/PI Apoptosis Detection Kit (Vazyme, A211-01) was used to detect drug effects on cancer cell apoptosis. GC cells were seeded in 12-well plates at a density of 1×10^5 cells per well and incubated with different formulations for 2 days. Afterwards, cells were collected and suspended in 100 μl binding buffer containing 2.5 μL Annexin V-FITC and 2.5 μL propidium iodide (PI) for 10 min in the darkness. Samples were run by flow cytometer and analyzed by FlowJo (*RRID:SCR_008520*).

Western blotting

SNU-16 and KATOIII were seeded in 6-well plates at a density of 5×10^5 cells per well with 10% FBS 1640 medium, and were incubated with SHP099, AZD4547 or combination therapy for 1 hour or 2 days. Primary human tumor cells derived from ascites of a FGFR2-amplified GC patient were incubated with different administrations for 1 hour. Mouse tumor tissues were collected after 6 hours of last drug administration and homogenized after snap freezing. Then tumor tissues and cells were lysed in cell lysis buffer (NCM Biotech, WB3100) containing 1% protease and phosphatase inhibitors (NCM Biotech, P002). 10 μg of protein was used to detect the expression levels of FGFR2-initiated downstream signaling molecules by SDS-PAGE, electro-transfer and immunoblotting with specific antibodies. The following antibodies were used: from Cell Signaling Technology, phospho-FGFR Tyr653/654 (Cell Signaling Technology Cat# 3476, 1:1000), SHP2 (3397T, 1:2000), phospho-SHP2 Tyr542 (3751T, 1:1000), ERK1/2 (4695T, 1:1000), phospho-ERK1/2 Thr202/Tyr204 (4370T, 1:2000), p38 (8690T, 1:1000), phospho-p38 Thr180/Tyr182 (4511T, 1:1000), AKT (9272S, 1:1000), phospho-AKT Ser473 (4060S, 1:2000), mTOR (2983T, 1:1000), phospho-mTOR Ser2448 (5536S, 1:1000), GAPDH (5174S, 1:1000), Anti-mouse IgG, HRP-linked Antibody(7076P2, 1:2000); from Santa Cruz Biotechnology, FGFR2 (sc-6930, 1:500); from Biosharp, Goat Anti-Rabbit IgG, HRP-linked Antibody(BL003A, 1:5000).

Cell surface marker staining

PBMCs were incubated with different therapies in the presence of 0.25 μg/ml human anti-CD3 antibody (InVivoMAb, #BE0001-2) and 1 μg/ml human anti-CD28 antibody (InVivoMAb, #BE0248) for 24 hours, and then stained with FITC-anti-CD8 (BD Biosciences, 555634), Percp-Cy5.5-anti-CD4 (Biolegend, 317428) and PE-anti-PD-1 (Biolegend, 329906) for 30 min. Samples were run by flow cytometer. The cellular supernatants were collected and detected by Cytometic Beed Array (CBA) human IFN-γ kit (BD Biosciences, 558456).

Intracellular staining

The intracellular interferon-γ (IFN-γ) expression in $CD8^+$ T cells was detected by a BD Biosciences intracellular staining kit according to the instructions. After different processing for 24 hours, PMBCs were firstly stained with FITC-anti-CD8 and Percp-Cy5.5-anti-CD4 on cell surface for 30 min, and then stained with PE-IFN-γ after fixation and permeabilization. Samples were then run by flow cytometer and analyzed by FlowJo (*RRID:SCR_008520*).

Cytotoxicity assay

To evaluate the tumor-killing capacity of drug-stimulated T cells in vitro, T cells were pretreated with different formulations for 2 days. SNU-16 cells labled with carboxyfluorescein succinimidyl ester (Sigma, 21888) were seeded into ultralow 96-well plates at a density of 2×10^4 cells per well as the target cells. Drug-stimualted T cells were then added into the well at an E:T ratio of 10:1, 20:1, 40:1 as the effector cells and incubated with target cells for 9h. Afterwards, cells were staind with propidium iodide (Sigma, 537059) for 10 min in the darkness and analyzed with flow cytometer.

Xenograft tumor models

Four to six-week-old female BALB/c nude mice (T cell deficient) were subcutaneously injected with 1×10^7 SNU-16 cells suspended in 100 μL PBS with 50% Matrigel (BD Biocoat, 356234). When the tumor volume reached approximately 100-150 mm^3, mice were randomized into 4 groups (n=5 per group) and started on treatment with PBS, SHP099 50 mg/kg, AZD4547 1.56 mg/kg, SHP099 50 mg/kg plus AZD4547 1.56 mg/kg. The dosage of medications used in animal experiments referred to previous researches(Wong et al., 2018; Xie et al., 2013). Drugs were delivered by oral gavage every day for 21 days. Tumor dimensions were measured every other day and tumor size was calculated as 0.5 × length × $width^2$. All mice were killed on day 28 after tumor implantation. Tumor tissues were harvested for further analysis. All animal experiments were approved by the Institutional Animal Care and Use Committee of Drum Tower Hospital (approval number: 2022AE01029).

Statistical analysis

GraphPad Prism (*RRID:SCR_002798*) was used to conduct statistical analysis and construct graphics. Data are presented as the means ± standard error of the mean (SEM) and compared by unpaired t test, linear regression t test, Welch's t test, Pearson's Chi-square test, Fisher's exact test, Wilcoxon Test, ordinary one-way ANOVA or two-way ANOVOA. $P < 0.05$ was considered statistically significant. ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.

Results

Recurrent FGFR2 gene amplification in Chinese GC patients

161 GC samples collected from Nanjing Drum Tower Hospital were performed with NGS. The top 5 most significantly altered genes were TP53 (61%), ARID1A (25%), CDH1 (16%), ERBB2 (12%) and PIK3CA (12%) (Fig. S1A). Meanwhile, CCNE1 (8%), ERBB2 (7%), FGFR2 (6.2%), MET (6%) and CCND1 (6%) were the top 5 most frequently amplified genes in the cohort (Fig. 1A and 1C). Notably, the proportion of FGFR2 amplification ranked third after CCNE1 and ERBB2 among all amplified genomes (Fig. 1A). We can find FGFR2-amplified GC patients also occupied quite a high portion in TCGA-STAD cohort (15/295; 5%) (Fig. 1B), further emphasizing the prevalence of FGFR2-amplified GC patients.

Moreover, in our cohort, patients with FGFR2 amplification tended to present later TNM stages, although not statistically significant in difference (Table S1 and Fig. S1B-D). Also, Patients harboring FGFR2 amplification in TCGA exhibited higher FGFR2 mRNA expression levels



Fig 1. Recurrent FGFR2 gene amplification in Chinese GC patients.

(A) Overview of genomic alterations in GC patient samples collected in Nanjing Drum Tower Hospital (n=161). The patient samples are shown on the x-axis. Information of TMB, stage, MSI-status and significantly altered genes are shown on the y-axis, with frequency of each alteration annotated on the left of the waterfall plot. Pie chart displaying the proportion of FGFR2 alterations in **(B)** TCGA STAD cohort (n=295) and **(C)** Nanjing Drum Tower Hospital cohort (n=161).

(P<0.0001) (Fig. S1E). And, FGFR2 mRNA expression showed a positive correlation with PTPN11 mRNA expression (P=0.0496, R^2=0.01468) (Fig. S1F), the chief coding gene of SHP2, suggesting a potential co-overexpression of SHP2 in patients with FGFR2 amplification.

SHP099 enhances the anti-tumor effects and overcomes the resistance of FGFR2 inhibitors in FGFR2-amplified GC

FGFR2-amplified GC cell lines SNU-16 and KATOIII were detected to exhibit relatively higher FGFR2 expression levels compared to other human GC cell lines (Fig. S2). Then, the anti-tumor capacity of FGFR2 inhibitor, SHP2 inhibitor monotherapy or combination therapy was detected *in vitro*. It demonstrated that the combination administration of AZD4547 and SHP099 significantly suppressed cell proliferation compared to AZD4547 monotherapy in both KATOIII (P<0.0001) and SNU-16 (P< 0.0001) (Fig. 2A and B). Moreover, in groups treated with high concentration of AZD4547, the combination therapy notably enhanced cancer cell apoptosis in both KATOIII (P=0.0001 Combo vs. SHP099; P<0.0001 Combo vs. AZD4547) and SNU-16 (P<0.0001 Combo vs. SHP099; P=0.0017 Combo vs. AZD4547) (Fig. 2C and D). The above results confirm that the combination of SHP099 and AZD4547 has a synergistic effect on tumor cell killing and apoptosis in FGFR2-amplified GC *in vitro*.

To unravel the mechanisms underlying the anti-tumor effects of combination therapy, we investigated the expression levels of key proteins of PI3K/AKT and MAPK pathways in KATOIII following drug treatment for 1 hour or 48 hours. While the combination of 3nM AZD4547 and 10 μM SHP099 might not have led to a stronger inhibition of phospho-FGFR and phospho-SHP2 compared to 10 nM AZD4547 single-agent treatment, it induced a more pronounced suppression of downstream signal pathways of FGFR2, particularly phospho-ERK1/2 (Fig. 2E). Interestingly, levels of phospho-p38, which is a crucial cascade mediating another MAPK pathway(Lee et al., 2020), remained unaffected by the medication. It's worth noting that although phospho-FGFR and phospho-SHP2 were further suppressed over time, AZD4547 single-agent treatment failed to sustain downstream signal suppression after 48 hours. In contrast, the combination treatment could continuously inhibit the downstream signaling molecules and overcome the feedback activation caused by prolonged treatment duration. Similar regulations of these phospho-proteins were also observed in another FGFR2-amplified GC cell line SNU-16 (Fig. 2F).

The synergistic efficacy of combining AZD4547 with SHP099 in primary tumor cells derived from a FGFR2 inhibitor-resistant GC patient

A 49-year-old Asian female was diagnosed with poorly-differentiated gastric signet-ring cell carcinoma (SRCC) through gastroscopy in November 2020. Subsequently, she underwent laparoscopic radical gastrectomy and received a 12-cycle biweekly chemotherapy regimen of Docetaxel and Tegafur from December 2020 to January 2021. However, serum alpha-fetoprotein (AFP) concentration began to rise in September 2021, and liver tumor metastasis rapidly ensued. Given that her tumor tissue NGS revealed an amplified FGFR2 copy number of 87.1, she commenced FGFR2 inhibitor treatment in March 2022 (Fig. 3A). During the medication period, she initially received partial response (PR) and experienced a transient reduction on her liver lesion, but rapidly came to progressive disease (PD) in December 2022, manifesting multiple lesions (Fig. 3B). Similarly, serum AFP level decreased after 2 months of medication but subsequently continued to rise, reaching up to 10,000 ng/ml (Fig. 3C). As a result, we inferred that the patient initially exhibited sensitivity to FGFR2 inhibitors but swiftly developed resistance. After taking FGFR2 inhibitor for 13 months, the patient developed ascites (Fig. 3D), and pathological examination confirmed the presence of tumor cells in her ascites (Fig. 3E). To further evaluate the synergistic efficacy of dual blocking FGFR2 and SHP2 in patient-derived GC cells, we treated tumor cells derived from the patient's ascites with AZD4547, SHP099 or their combination *in vitro* for 48 hours. Consistently, the data indicated that FGFR2 inhibitor-resistant tumor cells from her ascites were more sensitive to the combination therapy compared to



Fig 2. SHP099 enhances the antitumor effects and overcomes the resistance of FGFR2 inhibitors in FGFR2-amplified GC.

Sensitivity of KATOIII and SNU-16 to **(A)** SHP099, **(B)** AZD4547 or combination therapy with different concentration gradients. Effects of different treatments on cell apoptosis of **(C)** KATOIII and **(D)** SNU-16 after 48-hour drugs incubation. **(E)** KATOIII and **(F)** SNU-16 were incubated with vehicle, SHP099 10 μM, AZD4547 3nM or combination therapies for 1 hour or 48 hours, then cell lysates were immunoblotted for phospho-FGFR and total-FGFR2, phospho-SHP2 and total-SHP2, phospho-Erk and total-Erk, phospho-p38 and total-p38, phospho-AKT and total-AKT, and phospho-mTOR and total-mTOR. Data are shown as Mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. P values are detemined by ordinary one-way ANOVA or two-way ANOVA.

AZD4547 monotherapy (P<0.0001) (Fig. 3F). To elucidate the underlying mechanisms, we detected the expression levels of key proteins related to FGFR2-initiated PI3K/AKT and RAS/ERK pathways after incubating tumor cells with different treatment for 1 hour. Interestingly, we didn't observe a significant downregulation of phospho-SHP2 in groups with addition of SHP099. However, combination therapy exhibited relatively stronger inhibitory effects on phospho-FGFR and its downstream molecules, including phospho-AKT and phospho-mTOR. Furthermore, the addition of SHP099 significantly suppressed phospho-ERK1/2 (Fig. 3G), suggesting that SHP099 may overcome FGFR2 inhibitor resistance mainly by suppressing RAS/ERK pathway. This case suggests that the combination of AZD4547 and SHP099 has potential application value in clinical FGFR2 inhibitor-resistant patients.

The combination of SHP099 and AZD4547 has significant anti-tumor effects in SNU-16 xenograft nude mice

To evaluate the tumor-killing capacity of combining SHP099 with AZD4547 in FGFR2-amplified GC *in vivo*, we established a subcutaneous SNU-16 xenograft model in nude mice (Fig. 4A). As anticipated, combination administration remarkably diminished tumor growth *in vivo* compared to both AZD4547 (P<0.0001, Fig. 4C; P=0.0258, Fig. 4D) and SHP099 (P=0.0005, Fig. 4C; P=0.0832, Fig. 4D) monotherapy (Fig. 4B-D and S3). Moreover, there were no notable signs of weight loss or drug toxicity observed (Fig. 4E and S4). Furthermore, consistent with *in vitro* studies, similar regulatory patterns of molecules downstream of FGFR2 were observed in protein samples derived from mouse tumor tissues. We found that combination therapy led to a more significantly suppression than single-agent treatment, especially in phospho-AKT and phospho-mTOR (Fig. 4F). To sum up, these results confirm the curative effects, elucidate the action mechanisms, and demonstrate the safety profile of combining SHP099 with AZD4547 in an *in vivo* model.

SHP099 activates $CD8^+$ T cells and promotes its tumor-killing capacity *in vitro*

Our evidence suggested that the FGFR2-amplified group may be less likely to benefit from common immune therapies(Fuchs et al., 2018; Kim et al., 2018; Shitara et al., 2018; Wang et al., 2021). We observed that PD-L1 Combined Positive Score (CPS)-negative (CPS<1) occurred more frequently in FGFR2-amplified GC patients compared to unamplified group in Nanjing Drum Tower Hospital cohort (Fig. 5A and S5A). Similarly, in the TCGA-STAD cohort, FGFR2-amplified GC patients exhibited lower PD-L1 mRNA expression (Fig. 5B). Meanwhile, there existed no FGFR2-amplified patients with high microsatellite instability (MSI-H) in both Nanjing Drum Tower Hospital cohort (Fig. 5A and S5B) and TCGA-STAD cohort (Fig. 5C). Furthermore, in the TCGA-STAD cohort, FGFR2-amplified GC patients showed lower Tumor Mutation Burden (TMB) levels versus unamplified group (Fig. S5C).

Considering the immunosuppressive role of SHP2 under PD-1/PD-L1 signaling, we also evaluated the effects of SHP099/AZD4547 combination therapy on T-cell immune activation *in vitro*. After incubating human PBMCs with different drug therapies for 24 hours in the presence of human anti-CD3 and anti-CD28, we observed that only groups with the addition of SHP099 could significantly induce the production of IFN-γ in $CD8^+$ T cells (P=0.0133 SHP099 vs. CD3/CD28 group; P=0.0167 Combo vs. CD3/CD28 group) (Fig. 5D and S6). Similarly, utilizing CBA detection, we confirmed that PBMCs treated with SHP099 monotherapy (P=0.0053 vs. CD3/CD28 group) or combined therapy (P=0.01 vs. CD3/CD28 group) secreted more IFN-γ (Fig. 5E). It's worth noting that a notable up-regulation in $CD4^+$ T cells was also observed when incubated with combination treatment (P<0.0001 vs. CD3/CD28 group) (Fig. S7). Importantly, the cell viability of human PBMCs was not affected by drug treatment (Fig. 5F). Besides, T cells pre-stimulated by SHP099 monotherapy (P <0.0001 vs. CD3/CD28 group) or combination therapy (P<0.0001 vs. CD3/CD28 group) exhibited a more potent tumor-killing ability when incubated with FGFR2-amplified SNU-



Fig 3. The synergistic efficacy of combining AZD4547 with SHP099 in primary tumor cells derived from a FGFR2 inhibitor-resistant GC patient.

(A) Schematic of therapeutic process of the FGFR2-amplified GC patient who was previously sensitive to FGFR2 inhibitors but quickly became resistant. **(B)** Representative CT and MRI images of recurrent liver lesions at different time points. Liver lesions are indicated by yellow arrows. **(C)** Representive CT images displaying the occurrence and progression of ascites. Ascites are indicatied by yellow arrows. **(D)** Pathology of malignant asites from this FGFR2 inhibitor-resistant patient. Tumor cells are indicated by red arrows. **(E)** AFP concentration variations of the patient during FGFR2 inhibitors medication. **(F)** Sensitivity of cancer cells from FGFR2 inhibitor-resistant patient's asites to FGFR2 inhibitor AZD4547, SHP2 inhibitor SHP099 or combined administration with different concentration gradients. Data are shown as Mean ± SEM. *p < 0.05, ****p < 0.0001. P values are detemined by two-way ANOVA. **(G)** Tumor cells from asites were incubated with vehicle, SHP099 5 μM, AZD4547 3 μM or combination therapy for 1 hour, then cell lysates were immunoblotted for phospho-FGFR and total-FGFR2, phospho-SHP2 and total-SHP2, phospho-Erk and total-Erk, phospho-AKT and total-AKT, and phospho-mTOR and total-mTOR.



Fig 4. The combination of SHP099 and AZD4547 has significant anti-tumor effects in SNU-16 xenograft nude mice.

BALB/c nude mice were injected with 1×10^7 SNU-16 cancer cells and received different formulations by oral gavage every day upon tumor volumes reached 100-150 mm^3. **(A)** Schematic of SHP099 and AZD4547 therapeutic schedule in FGFR2-amplified SNU-16 subcutaneous xenograft model. **(B)** Body weights, **(C)** tumor volumes and **(D)** tumor weights of different groups. **(E)** Representative images of tumors. **(F)** Tumors were harvested 6 hours after the last dose of drugs, and cell lysates from tumor tissues were immunoblotted for phospho-FGFR and total-FGFR2, phospho-SHP2 and total-SHP2, phospho-Erk and total-Erk, phospho-AKT and total-AKT, and phospho-mTOR and total-mTOR. Data are shown as Mean±SEM. ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. P values are detemined by ordinary one-way ANOVA or two-way ANOVA.



Fig 5. SHP099 activates CD8$^+$ T cells and promotes its tumor-killing capacity *in vitro*.

(A) Overview of FGFR2 alterations individually in GC patients from Nanjing Drum Tower hospital cohort. **(B)** PD-L1 mRNA expression levels were analyzed between FGFR2-amplified group (n=13) and FGFR2-unamplified group (n=250) from TCGA-STAD cohort. **(C)** Proportions of MSI-H or MSS in FGFR2-amplified group (n=12) and FGFR2-unamplified group (n=237) from TCGA-STAD cohort. Human peripheral blood mononuclear cells (PBMCs) were incubated with different administrations in the presence of 0.25 μg/ml human anti-CD3 and 1 μg/ml human anti-CD28. Proportions of **(D)** IFN-γ/CD8$^+$ cells were detected by flow cytometry assay after 24-hour of drugs incubation. **(E)** Expression levels of IFN-γ in cellular supernatant were measured by Cytometric Bead Array (CBA) assay after 24-hour of drugs incubation. **(F)** Cell viability of human PBMCs after 48-hour of drugs incubation. **(G, H)** After 48-hour of advance drugs stimulation in human PBMCs, cytotoxicities of human PBMCs against SNU-16 at different E:T ratios of 10:1, 20:1, 40:1 were analyzed by flow cytometry assay after CFSE/PI

16 cells *in vitro* (Fig. 5G and H). Based on the above results, our data suggest that SHP099 may also synergize with FGFR2 inhibitor by eliciting $CD8^+$ T-cell anti-tumor immunity and improving the inhibitory TIME.

Discussion

FGFR2 amplification is a common form of genetic variations in GC, and it was identified in 5% of GC patients in TCGA-STAD cohort. Meanwhile, in our study, FGFR2 amplification occupied around 6.2% of GC patients in Nanjing Drum Tower Hospital cohort. And, it is conclusively shown that FGFR2 amplification of GC is closely related to poor prognosis. Previous study demonstrated that FGFR2 amplification was significantly associated with lymph node metastasis, poor tumor differentiation and worse survival in GC(Kim, Kim, & Jang, 2019). Consistently, FGFR2-amplifed GC patients were observed to exhibit more advanced tumor stages in our cohort. It prompted that FGFR2 amplification is a potential therapeutic target for GC.

Although FGFR2-targeted therapy has made some progress in GC treatment, there still exists problems such as low drug sensitivity and susceptibility to drug resistance. We reported a typical clinical case of a FGFR2-amplified gastric SRCC patient, showing symptoms of liver metastasis less than one year after radical gastrectomy. The patient received FGFR2 inhibitors and achieved PR after 2-month medication, with a duration of response only 7 months. This case also indicates that FGFR2-amplifed GC patients tend to have poorer prognosis and develop resistance to FGFR2 inhibitors in relative short period.

In terms of the mechanisms of FGFR2 inhibitors resistance, as early as 2013, the research in *Cancer Discovery* revealed the potential causes of FGFR2 inhibitors resistance in FGFR3-mutated bladder cancer patients. It demonstrated that the bypass EGFR-mediated signaling activation would reduce the efficacy of FGFR inhibitors. As a result, the drug sensitivity of FGFR3-mutated bladder cancer patients to FGFR inhibitors was limited, leading to the occurrence of FGFR inhibitors resistance(Herrera-Abreu et al., 2013). Another research conducted a more in-depth exploration of this mechanism. Researchers found that in iCCA with FGFR2 fusion, feedback activation of downstream RAS/ERK, PI3K/AKT pathways mediated by EGFR alternative pathway is a significant contributor to FGFR2 inhibitors' resistance. By combining EGFR inhibitor with FGFR2 inhibitor, the feedback activation of downstream pathways was successfully relieved(Wu et al., 2022). The existing researches have recognized the crucial role played by feedback activation in RTK inhibitors resistance. And, it cannot be ruled out that there are other bypass RTK activation besides EGFR, such as HER-2, cMET, FGFR3, etc(Huang et al., 2024; Ryan et al., 2020).

SHP2 is a common molecule downstream of all RTKs. Several studied have documented that SHP2 inhibitor displayed superior anti-tumor capacity and synergistic combination efficacy with RTK inhibitors in RTK driven tumors(Chen et al., 2016; Fedele et al., 2021; Wong et al., 2018). Since SHP2 transduces signaling from all RTKs, we speculate that SHP2 inhibition can not only directly promote the anti-tumor effects of FGFR2 inhibitors, but also overcome FGFR2 inhibitors resistance by blocking all possible alternative RTK pathways. Our study first established that SHP099 can effectively promote the direct anti-tumor capacity of AZD4547 in different FGFR2-amplified GC cell lines by further suppressing downstream RAS/ERK and PI3K/AKT pathways. Meanwhile, SHP099 could continuously inhibit upstream and downstream signaling molecules and overcome FGFR2 inhibitor resistance in long-term drug stimulated tumor cells. On the contrary, AZD4547 monotherapy exhibited obvious feedback activation of downstream pathways. We also validated the combined efficacy of SHP099 and AZD4547 in a SNU-16 cell-derived xenograft (CDX) nude mouse model, and no significant drug toxicity was observed. For further research, we isolated primary tumor cells from the FGFR2-inhibitor resistant patient's ascites. It was observed that the combination treatment with SHP099 could enhance the anti-tumor efficacy of AZD4547 by inhibiting downstream RAS/ERK and PI3K/AKT pathways. By dual blocking FGFR2 and SHP2, we successfully overcame FGFR2 inhibitors resistance by suppressing FGFR2-iniated downstream pathways in FGFR2 inhibitor-resistant patient's cancer cells. These findings provide a potential effective approach for overcoming FGFR2 inhibitors resistance.

Previous studies only focused on drug resistance caused by bypass signaling activation of a specific RTK gene, while our study utilized SHP2 inhibitor to counteract feedback activation of downstream signaling pathways caused by all RTK activation, providing a widely applicable combination therapy model. Apart from the targeted tumor-killing capacity, we also validated the immune regulation role of SHP2 inhibition in treating FGFR2-amplified GC patients. FGFR2-amplified patients in TCGA-STAD cohort tended to have poorer PD-L1 mRNA expression and lower TMB levels compared to the unamplified group, while MSS occurred more frequently in FGFR2-amplified group. These characteristics are inextricably correlated with reduced responsiveness to anti-PD-1/PD-L1 therapy and poorer immune infiltration(Fuchs et al., 2018; Kim et al., 2018; Shitara et al., 2018; Wang et al., 2021). Meanwhile, SHP2 serves as a downstream molecule in the PD-1 signaling pathway. It has been confirmed that SHP2 can be recruited and bound to PD-1, thus inhibiting cytotoxic T cells activation by suppressing CD28 and TCR signals(Ai et al., 2020; Liu et al., 2020). Previous study has demonstrated that T-cell SHP2-deficient mice bearing colitis-associated cancer showed enhanced cytotoxicity of $CD8^+$ T cells and reduced tumor sizes(Liu et al., 2017), corroborating that SHP2 inhibition can facilitate T cell anti-tumor immunity. In addition, the combination of SHP2 inhibitor and anti-PD-1 antibody has been proved to have synergistic anti-tumor effects in colon cancer by activating cytotoxic $CD8^+$ T cells and normalizing TIME(Zhao et al., 2019). The above evidence confirmed the enormous potential value of inhibiting SHP2 in regulating anti-tumor immunity. Although several researches have revealed that SHP2 inhibitor can be ideal synergistic combination partners for various RTK inhibitors from the perspective of targeted therapy, including MET(Pudelko et al., 2020), EGFR(Liu et al., 2021; Sun et al., 2020; Xia et al., 2021) and RET inhibitors(Lu et al., 2024), currently no in-depth study focusing on its immune regulatory function has been conducted. Our study demonstrated for the first time *in vitro* that SHP099 combing with AZD4547 down-regulated the T-cell exhaustion molecule PD-1 and up-regulated IFN-γ secretion in $CD8^+$ T cells, leading to an enhanced tumor-killing capacity of cytotoxic T lymphocytes in FGFR2-amplifed GC cell line.

Taken together, our study collectively affirmed that the combination of SHP099 and AZD4547 can not only promote the targeted tumor-killing effects and overcome AZD4547 drug resistance, but also activate T cell immunity in FGFR2-amplified GC (Fig. 6). We have validated the utility and feasibility of combining SHP2 inhibitor to FGFR2 inhibitor in FGFR2-amplified GC patients, providing an effective combination mode with both targeted intervention and immune regulation. Moreover, we also furnished sufficient evidence for the combination of RTK inhibitors and SHP2 inhibitors for all RTK-driven pan-cancer treatment.



Fig 6. Schematic of the mechasims of blocking SHP2 and FGFR2 in inhibiting tumor progression by targeted therapy and immune intervention.

On one hand, SHP2 inhibitor can boost the tumor-cytotoxicity effects of FGFR2 inhibitor by inhibiting PI3K/AKT and RAS/ERK pathways in FGFR2-amplified GC, and overcome FGFR2 inhibitor resistance caused by feedback activation. On the other hand, SHP2 inhibitor can activate $CD8^+$ T cells to kill tumor cells, suggesting its synergizing effects with FGFR2 inhibitor by enhancing T cell-mediated anti-tumor immune responses. Our results demonstrate the utility and feasibility of combining SHP2 inhibitor to FGFR2 inhibitor in GC patients with FGFR2 amplification.

Data availability

Patients' data were from The Cancer Genome Atlas Program (TCGA)me, doi: 10.1038/nature13480. All data generated or analyzed during this study are included in the manuscript and supporting files; source data files have been provided for all figures.

Acknowledgements

We would like to thank OrigiMed for the kind help of NGS and Nanjing University Chao Yan laboratory for the generous donation of KATOIII cell line.

Additional information

Author contributions

Y.W. and T.S. designed the study, supervised the entire study and reviewed the manuscript. Y.Z. performed the experiments, analyzed the data and wrote the manuscript with assistance from H.W. and Y.P. Y.W. edited the pictures. X.S., T.S., J.S., L.Y. helped to perform the experiments.

Ethics Statement

The study was conducted with the code of ethics of the World Medical Association (Declaration of Helsinki) and approved by the Ethics Committee of Nanjing Drum Tower Hospital (No. 2021-324-01). Human samples used in this study obtained patients' consent. All animal experiments were approved by the Institutional Animal Care and Use Committee of Drum Tower Hospital (approval number: 2022AE01029).

Funding

Funder	Grant reference number	Author
MOST | National Natural Science Foundation of China (NSFC)	82403862	Yue Wang
MOST | National Natural Science Foundation of China (NSFC)	82403835	Tao Shi

Additional files

Supplementary data

References

Ahn S., Lee J., Hong M., Kim S. T., Park S. H., Choi M. G., ..., Kim K. M (2016) FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. *Mod Pathol* **29**:1095-1103 https://doi.org/10.1038/modpathol.2016.96

Ai L., Xu A., Xu J (2020) Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. *Adv Exp Med Biol* **1248**:33-59 https://doi.org/10.1007/978-981-15-3266-5_3

Ajani J. A., D'Amico T. A., Bentrem D. J., Chao J., Cooke D., Corvera C., ..., Pluchino L. A (2022) Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* **20**:167-192 https://doi.org/10.6004/jnccn.2022.0008

Babina I. S., Turner N. C (2017) Advances and challenges in targeting FGFR signalling in cancer. *Nat Rev Cancer* **17**:318-332 https://doi.org/10.1038/nrc.2017.8

Chen Y. N., LaMarche M. J., Chan H. M., Fekkes P., Garcia-Fortanet J., Acker M. G., ..., Fortin P. D (2016) Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. *Nature* **535**:148-152 https://doi.org/10.1038/nature18621

Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* **513**:202-209 https://doi.org/10.1038/nature13480

Du Z., Lovly C. M (2018) Mechanisms of receptor tyrosine kinase activation in cancer. *Mol Cancer* **17**:58 https://doi.org/10.1186/s12943-018-0782-4

Fedele C., Li S., Teng K. W., Foster C. J. R., Peng D., Ran H., ..., Neel B. G (2021) SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. *J Exp Med* **218** https://doi.org/10.1084/jem.20201414

Fuchs C. S., Doi T., Jang R. W., Muro K., Satoh T., Machado M., ..., Yoon H. H (2018) Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. *JAMA Oncol* **4**:e180013 https://doi.org/10.1001/jamaoncol.2018.0013

Gordon A., Johnston E., Lau D. K., Starling N (2022) Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments. *Onco Targets Ther* **15**:1183-1196 https://doi.org/10.2147/ott.S282718

Guan W. L., He Y., Xu R. H (2023) Gastric cancer treatment: recent progress and future perspectives. *J Hematol Oncol* **16**:57 https://doi.org/10.1186/s13045-023-01451-3

Herrera-Abreu M. T., Pearson A., Campbell J., Shnyder S. D., Knowles M. A., Ashworth A., Turner N. C (2013) Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. *Cancer Discov* **3**:1058-1071 https://doi.org/10.1158/2159-8290.Cd-12-0569

Huang P., Ji F., Cheung A. H., Fu K., Zhou Q., Ding X., ..., Wong C. C (2024) Peptostreptococcus stomatis promotes colonic tumorigenesis and receptor tyrosine kinase inhibitor resistance by activating ERBB2-MAPK. *Cell Host Microbe* https://doi.org/10.1016/j.chom.2024.07.001

Hur J. Y., Chao J., Kim K., Kim S. T., Kim K. M., Klempner S. J., Lee J (2020) High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. *Pathol Res Pract* **216**:152878 https://doi.org/10.1016/j.prp.2020.152878

Jang J., Kim H. K., Bang H., Kim S. T., Kim S. Y., Park S. H., ..., Kim K. M (2017) Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model. *Transl Oncol* **10**:469-475 https://doi.org/10.1016/j.tranon.2017.03.001

Janjigian Y. Y., Shitara K., Moehler M., Garrido M., Salman P., Shen L., ..., Ajani J. A (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet* **398**:27-40 https://doi.org/10.1016/s0140-6736(21)00797-2

Jogo T., Nakamura Y., Shitara K., Bando H., Yasui H., Esaki T., ..., Yoshino T (2021) Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. *Clin Cancer Res* **27**:5619-5627 https://doi.org/10.1158/1078-0432.Ccr-21-1414

Kang C (2023) Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma. *Target Oncol* **18**:981-989 https://doi.org/10.1007/s11523-023-00998-y

Katoh M., Loriot Y., Brandi G., Tavolari S., Wainberg Z. A., Katoh M (2024) FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. *Nat Rev Clin Oncol* **21**:312-329 https://doi.org/10.1038/s41571-024-00869-z

Katoh M., Nakagama H (2014) FGF receptors: cancer biology and therapeutics. *Med Res Rev* **34**:280-300 https://doi.org/10.1002/med.21288

Kim H. S., Kim J. H., Jang H. J (2019) Pathologic and prognostic impacts of FGFR2 amplification in gastric cancer: a meta-analysis and systemic review. *J Cancer* **10**:2560-2567 https://doi.org/10.7150/jca.29184

Kim H. S., Kim J. H., Jang H. J., Han B., Zang D. Y (2019) Pathological and Prognostic Impacts of FGFR2 Overexpression in Gastric Cancer: A Meta-Analysis. *J Cancer* **10**:20-27 https://doi.org/10.7150/jca.28204

Kim S. T., Cristescu R., Bass A. J., Kim K. M., Odegaard J. I., Kim K., ..., Kang W. K (2018) Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. *Nat Med* **24**:1449-1458 https://doi.org/10.1038/s41591-018-0101-z

Koh J., Nam S. K., Roh H., Kim J., Lee B. C., Kim J. W., ..., Lee H. S (2019) Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type. *Genes Chromosomes Cancer* **58**:12-22 https://doi.org/10.1002/gcc.22683

Lee S., Rauch J., Kolch W (2020) Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity. *Int J Mol Sci* **21** https://doi.org/10.3390/ijms21031102

Li J., Jie H. B., Lei Y., Gildener-Leapman N., Trivedi S., Green T., ..., Ferris R. L (2015) PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. *Cancer Res* **75**:508-518 https://doi.org/10.1158/0008-5472.Can-14-1215

Liu C., Lu H., Wang H., Loo A., Zhang X., Yang G., ..., Hao H. X (2021) Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling. *Clin Cancer Res* **27**:342-354 https://doi.org/10.1158/1078-0432.Ccr-20-2718

Liu Q., Qu J., Zhao M., Xu Q., Sun Y (2020) Targeting SHP2 as a promising strategy for cancer immunotherapy. *Pharmacol Res* **152**:104595 https://doi.org/10.1016/j.phrs.2019.104595

Liu W., Guo W., Shen L., Chen Z., Luo Q., Luo X., ..., Sun Y (2017) T lymphocyte SHP2-deficiency triggers anti-tumor immunity to inhibit colitis-associated cancer in mice. *Oncotarget* **8**:7586-7597 https://doi.org/10.18632/oncotarget.13812

Lu X., Yu R., Li Z., Yang M., Dai J., Liu M (2024) JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers. *Cancer Lett* **582**:216517 https://doi.org/10.1016/j.canlet.2023.216517

Paul M. D., Hristova K (2019) The RTK Interactome: Overview and Perspective on RTK Heterointeractions. *Chem Rev* **119**:5881-5921 https://doi.org/10.1021/acs.chemrev.8b00467

Pearson A., Smyth E., Babina I. S., Herrera-Abreu M. T., Tarazona N., Peckitt C., ..., Turner N. C (2016) High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. *Cancer Discov* **6**:838-851 https://doi.org/10.1158/2159-8290.Cd-15-1246

Pudelko L., Jaehrling F., Reusch C., Vitri S., Stroh C., Linde N., ..., Karachaliou N (2020) SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations. *iScience* **23**:101832 https://doi.org/10.1016/j.isci.2020.101832

Ryan M. B., Fece de la Cruz F., Phat S., Myers D. T., Wong E., Shahzade H. A., ..., Corcoran R. B. (2020) Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS(G12C) Inhibition. *Clin Cancer Res* **26**:1633-1643 https://doi.org/10.1158/1078-0432.Ccr-19-3523

Shitara K., Özgüroğlu M., Bang Y. J., Di Bartolomeo M., Mandalà M., Ryu M. H., ..., Fuchs C. S. (2018) Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. *Lancet* **392**:123-133 https://doi.org/10.1016/s0140-6736(18)31257-1

Smyth E. C., Nilsson M., Grabsch H. I., van Grieken N. C., Lordick F. (2020) Gastric cancer. *Lancet* **396**:635-648 https://doi.org/10.1016/s0140-6736(20)31288-5

Sodir N. M., Pathria G., Adamkewicz J. I., Kelley E. H., Sudhamsu J., Merchant M., ..., Maddalo D (2023) SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment. *Cancer Discov* **13**:2339-2355 https://doi.org/10.1158/2159-8290.Cd-23-0383

Song Y., Zhao M., Zhang H., Yu B (2022) Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials. *Pharmacol Ther* **230**:107966 https://doi.org/10.1016/j.pharmthera.2021.107966

Song Z., Wu Y., Yang J., Yang D., Fang X (2017) Progress in the treatment of advanced gastric cancer. *Tumour Biol* **39**:1010428317714626 https://doi.org/10.1177/1010428317714626

Sun Y., Meyers B. A., Czako B., Leonard P., Mseeh F., Harris A. L., ..., Jones P (2020) Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib. *Cancer Res* **80**:4840-4853 https://doi.org/10.1158/0008-5472.Can-20-1634

Van Cutsem E., Bang Y. J., Mansoor W., Petty R. D., Chao Y., Cunningham D., ..., Landers D. (2017) A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. *Ann Oncol* **28**:1316-1324 https://doi.org/10.1093/annonc/mdx107

Wainberg Z. A., Enzinger P. C., Kang Y. K., Qin S., Yamaguchi K., Kim I. H., ..., Lee K. W (2022) Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. *Lancet Oncol* **23**:1430-1440 https://doi.org/10.1016/s1470-2045(22)00603-9

Wang D., Wang N., Li X., Chen X., Shen B., Zhu D., ..., Shu Y (2021) Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia. *Gastric Cancer* **24**:823-834 https://doi.org/10.1007/s10120-021-01175-8

Wei L., Sun J., Zhang N., Zheng Y., Wang X., Lv L., ..., Yang M (2020) Noncoding RNAs in gastric cancer: implications for drug resistance. *Mol Cancer* **19**:62 https://doi.org/10.1186/s12943-020-01185-7

Wong G. S., Zhou J., Liu J. B., Wu Z., Xu X., Li T., ..., Bass A. J (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. *Nat Med* **24**:968-977 https://doi.org/10.1038/s41591-018-0022-x

Wu Q., Zhen Y., Shi L., Vu P., Greninger P., Adil R., ..., Bardeesy N (2022) EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. *Cancer Discov* **12**:1378-1395 https://doi.org/10.1158/2159-8290.Cd-21-1168

Xia L., Yang F., Wu X., Li S., Kan C., Zheng H., Wang S (2021) SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness. *Cancer Cell Int* **21**:337 https://doi.org/10.1186/s12935-021-02056-x

Xie L., Su X., Zhang L., Yin X., Tang L., Zhang X., ..., Ji Q (2013) FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. *Clin Cancer Res* **19**:2572-2583 https://doi.org/10.1158/1078-0432.Ccr-12-3898

Yang Y. M., Hong P., Xu W. W., He Q. Y., Li B (2020) Advances in targeted therapy for esophageal cancer. *Signal Transduct Target Ther* **5**:229 https://doi.org/10.1038/s41392-020-00323-3

Zhao J. J., Yap D. W. T., Chan Y. H., Tan B. K. J., Teo C. B., Syn N. L., ..., Sundar R (2022) Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. *J Clin Oncol* **40**:392-402 https://doi.org/10.1200/jco.21.01862

Zhao M., Guo W., Wu Y., Yang C., Zhong L., Deng G., ..., Sun Y (2019) SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade. *Acta Pharm Sin B* **9**:304-315 https://doi.org/10.1016/j.apsb.2018.08.009

Peer reviews

Reviewer #1 (Public review):

The manuscript entitled "Blocking SHP2 1 benefits FGFR2 inhibitor and overcomes its resistance in 2 FGFR2-amplified gastric cancer" by Zhang, et al., reports that FGFR2 was amplification in 6.2% (10/161) of gastric cancer samples and that dual blocking SHP2 and FGFR2 enhanced the effects of FGFR2 inhibitor (FGFR2i) in FGFR2-amplified GC both in vitro and in vivo via suppressing RAS/ERK and PI3K/AKT pathways. Furthermore, the authors also showed that SHP2 blockade suppressed PD-1 expression and promoted IFN-γ secretion of CD8+ 46 T cells, enhancing the cytotoxic functions of T cells. Thus, the authors concluded that dual blocking SHP2 and FGFR2 is a compelling strategy for treatment of FGFR2-amplified

gastric cancer. Although the finding is interesting, the finding that FGFR2 is amplified in gastric cancer and that FGFR inhibitors have some effect on treating gastric cancer is not novel. The data quality is not high, the effects of double inhibitions are not significant. It appears that the conclusions are largely overstated, the supporting data is weak and not compelling.

The data in Figure 1 is not novel; similar data have been reported elsewhere.

It is unclear why the two panels in fig 2a and 2b can not be integrated into one panel, which will make it easier to compare the activities.

The synergetic effects of azd4547 and shp099 are not significant in Fig 2e and 2f, as well as in Fig. 3g and Fig. 4f

Data in Fig. 5 is weak and can be removed. It is unclear why FGFR inhibitor has some activities toward t cells since t cells do not express FGFR.

https://doi.org/10.7554/eLife.104060.2.sa3

Reviewer #2 (Public review):

Summary:

This manuscript reports the application of a combined targeted therapeutic approach to gastric cancer treatment. The RTK, FGFR2 and the phosphatase, SHP2 are targeted with existing drugs; AZD457 and SHP099, respectively. Having shown increased mRNA levels of FGFR2 and SHP2 in a patient population and highlighted the issue of resistance to single therapies the combination of inhibitors is shown to reduce cancer-related signalling in two gastric cell lines. The efficacy of the dual therapy is further demonstrated in a single patient case study and mouse xenograft models. Finally, the rationale for SHP2 inhibition is shown to be linked to immune response.

Strengths:

The data is generally well presented, and the study invokes a novel patient data set which could have wider value. The study provides additional evidence to support the combined therapeutic approach of RTK and phosphatase inhibition.

Weaknesses:

Combined therapy approaches targeting RTKs and SHP2 have been widely reported. Indeed, SHP099 in combination with FGFR inhibitors has been shown to overcome adaptive resistance in FGFR-driven cancers. Furthermore, the inhibition of SHP2 has been documented to have important implications in both targeting proliferative signalling as well as immune response. Thus, it is difficult to see novelty or a significant scientific advance in this manuscript. Although the data is generally well presented, there is inconsistency in the interpretation of the experimental outcomes from ex vivo, patient and mouse systems investigated. In addition, the study provides only minor or circumstantial understanding of the dual mechanism.

Using data from a 161 patient cohort FGFR2 was identified as displaying amplification of FGFR2 in ~6% with concomitant elevation of mRNA of patients which correlated with PTPN11 (SHP2) mRNA expression. The broader context of this data is of value and could add a different patient demographic to other data on gastric cancer. However, there is no detail on patient stratification or prior therapeutic intervention.

Comments on revisions: This has been attended to in the revised version

In SNU16 and KATOIII cells the combined therapy is shown to be effective and appears to be correlated with increase apoptotic effects (i.e. not immune response).

Fig 2E suggests that the combined therapy in SNU16 cells is little better than FGFR2-directed AZD457 inhibitor alone, particularly at the higher dose.

The individual patient case study described via Fig 3 suggests efficacy of the combined therapy (at very high dosage), however the cell biopsies only show reduced phosphorylation of ERK, but not AKT. This is at odds with the ex vivo cell-based assays. Thus, it is not clear how relevant this study is.

The mouse xenograft study shows a convincing reduction in tumor mass/volume and a clear reduction in pAKT, whilst pERK remains largely unaffected by the combined therapeutic approach. This is in conflict with the previous data which seems to show the opposite effect.

Comments on revisions: The authors have clarified this point

In all, the impact of the dual therapy is unclear with respect to the two pathways mediated by ERK and AKT.

Finally, the authors demonstrate the impact of SHP2 on PD-1 expression and propose that the SHP099/AZD4547 combination therapy significantly induces the production of IFN-γ in CD8+ T cells. This part of the study is unconvincing and would benefit from an investigation of the tumor micro-environment to assess T cell infiltration.

https://doi.org/10.7554/eLife.104060.2.sa2

Reviewer #3 (Public review):

Summary:

Fibroblast growth factor receptor 2 (FGFR2) is a receptor tyrosine kinase that can be amplified in gastric cancer and serves as a potential therapeutic target for this patient population. However, targeting FGFR2 has shown limited efficacy. Thus, this study seeks to identify additional molecules that can be effectively targeted in FGFR2 amplified gastric cancer, with a focus on Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2). The authors first demonstrate that 6% of gastric cancer patients in a cohort of human patient samples exhibit FGFR2 amplification. Furthermore, they demonstrate that FGFR2 mRNA expression is positively correlated with PTPN11 gene expression (which is the gene that encodes the SHP2 protein). Using human gastric cancer cell lines with amplified FGFR2, the authors then test the effects of combining the FGFR inhibitor AZD4547 with the SHP2 inhibitor SHP099 on tumor cell death and signaling molecules. They demonstrate that combining the two inhibitors is more effective at tumor cell killing and reducing activation of downstream signaling pathways than either inhibitor alone. In further studies, the authors obtained gastric cancer cells with FGFR2 amplification from a patient that was treated with FGFR2 inhibitor. While this patient initially showed a partial response, the patient ultimately progressed, demonstrating resistance to FGFR2 inhibition. Following isolation of tumor cells from the patient's ascites, the authors demonstrate that these cells are sensitive to the combination treatment of AZD4547 and SHP099. Further studies were performed using a xenograft model using athymic nude mice in which the combination of SHP099 and AZD4547 were found to reduce tumor growth more significantly than either treatment alone. Finally, the authors demonstrate using an in vitro culture model that this combination treatment enhances T cell mediated cytotoxicity. The authors conclude that targeting FGFR2 and SHP2 represents a potential combination strategy in gastric patients with FGFR2 amplification.

Strengths:

The authors demonstrate that FGFR2 amplification positively correlates with PTPN11 in human gastric cancer samples, providing a rationale for combination therapies. Furthermore, convincing data are provided demonstrating that targeting both FGFR and SHP2 is more effective than targeting either pathway alone using in vitro and in vivo models. The use of cells derived from a gastric cancer patient that progressed following treatment with an FGFR inhibitor is also a strength. The findings from this study support the conclusion that SHP2 inhibitors enhance the efficacy of FGFR-targeted therapies in cancer patients. This study also suggests that targeting SHP2 may also be an effective strategy for targeting cancers that are resistant to FGFR-targeted therapies.

Weaknesses:

The main caveat with these studies is the lack of an immune competent model with which to test the finding that this combination therapy enhances T cell cytotoxicity in vivo.

https://doi.org/10.7554/eLife.104060.2.sa1

Author response:

The following is the authors' response to the original reviews

> ***Public Reviews:***
>
> ***Reviewer #1 (Public review):***
>
> *The data in Figure 1 is not novel, similar data has been reported elsewhere.*

We are grateful for the critical evaluation of our finding. Although there have been a few researches indicating the prevalence of FGFR2-amplified GC patients, our research provided a novel dataset of 161 GC patients using next-generation sequencing (NGS) in China, further emphasizing the high frequency of FGFR2 amplification in gastric cancer patients. Moreover, the proportion of FGFR2-amplified GC patients in our center (6.2%) is relatively higher than that of TCGA cohort (5%).

We have transferred the original Figure 1C and 1D to the supplementary figures, and constructed a novel pie chart for Nanjing Drum Tower Hospital cohort to compare with the TCGA cohort.

> *It is unclear why the two panels in Fig 2a and 2b can not be integrated into one panel, which will make it easier to compare the activities.*

Thanks for pointing this out. In the first figure of Figure 2a and 2b, we performed gradient concentration CCK8 detection on the cytotoxicity of SHP099 against tumor cells. In the second figure, we selected 10 μm (IC50) as the fixed concentration of SHP099 for combined efficacy testing with gradient concentration of AZD4547. Moreover, the units of the horizontal axis in both figure 2a and 2b cannot be unified. Therefore, we believe that the two figures in figures 2a and 2b are not suitable for merging into one figure.

For the convenience of observation, we integrated the first panel of figure 2a and 2b into one panel, and integrated the second panel in the same way.

> *The synergetic effects of azd4547 and shp099 are not significant in Fig 2e and 2f, as well as in Fig. 3g and fig. 4f*

In Fig 2e and 2f, we not only analyzed the synergetic effects of 3 nM (a relatively lower dose) AZD4547 and 10 μm SHP099, but also 10 nM (a relatively higher dose) AZD4547 and 10 μm SHP099. The synergetic effects of different dosage combinations should be compared

correctly. From our perspective, the combination treatment led to a stronger inhibition of phospho-FGFR, phospho-SHP2 and FGFR2-initiated downstream signaling molecules, especially in KATOIII.

For ease of comparison, we circled 10 μm SHP099, 10nM AZD4547 and 10nM AZD4547+10 μm SHP099 in red.



Author response image 1.



Author response image 2.

We also circled 10μM SHP099, 3nM AZD4547 and 3nM AZD4547+10 μm SHP099 in blue.



Author response image 3.



Author response image 4.

For ease of comparison, we also conducted grayscale value analysis and normalization using image J.



Author response image 5.



Author response image 6.



Author response image 7.



Author response image 8.

In Fig. 3g, the combination therapy exhibited relatively stronger inhibitory effects on phospho-ERK, phospho-AKT and phospho-mTOR.

For ease of comparison, we conducted grayscale value analysis and normalization using image J.

The unclear effect of combination therapy may be due to the presence of impurities other than tumor cells in patient's ascites.



Author response image 9.

In Fig. 4f, it was obvious that phospho-AKT and phospho-mTOR were further suppressed in combination group.

For ease of comparison, we conducted grayscale value analysis and normalization using image J.



Author response image 10.

Therefore, in our opinions, our data could relatively sufficiently confirm the synergetic effects of AZD4547 and SHP099.

> *Data in Fig. 5 is weak and can be removed. It is unclear why FGFR inhibitor has some activities toward t cells since t cells do not express FGFR.*

The activation effect of SHP099 on T cells has been validated in many articles. In a previous study published in Cancer Immunology Research, it was pointed out that the combination of FGFR2 inhibitor erdafitinib and PD-1 antibody can activate T cells and downregulate T cell surface exhaustion related factors (including PD-1) in vivo Therefore, the anti-tumor immune effect of FGFR2 inhibitor cannot be ignored. Although T cells do not express FGFR, FGFR2 inhibitors may still affect PD-1 expression on the surface of T cells in some other ways, which requires further research. We have deleted fig.5D in our article. We believe that the combination of FGFR2 inhibitor and SHP2 inhibitor not only has a direct killing effect on tumor cells, but also promotes anti-tumor immunity by activating T cells. Therefore, we believe that the in vitro data in Figure 5 is also meaningful.

> ***Reviewer #2 (Public review):***
>
> *Strengths:*
>
> *The data is generally well presented and the study invokes a novel patient data set which could have wider value. The study provides additional evidence to support the combined therapeutic approach of RTK and phosphatase inhibition.*

We sincerely thank the reviewer for the critical evaluation and appreciation of our findings.

> *Weaknesses:*
>
> *Combined therapy approaches targeting RTKs and SHP2 have been widely reported. Indeed, SHP099 in combination with FGFR inhibitors has been shown to overcome adaptive resistance in FGFR-driven cancers. Furthermore, the inhibition of SHP2 has been documented to have important implications in both targeting proliferative signalling as well as immune response. Thus, it is difficult to see novelty or a significant scientific advance in this manuscript. Although the data is generally well presented, there is inconsistency in the interpretation of the experimental outcomes from ex vivo, patient and mouse systems investigated. In addition, the study provides only minor or circumstantial understanding of the dual mechanism.*

We acknowledge that our research on the mechanism of dual inhibition is not deep enough. There remain more in-depth mechanisms of the combination of SHP2 inhibitor and RTK inhibitors needed to be explored, and it would be the main direction of our future study.

> *Using data from a 161 patient cohort FGFR2 was identified as displaying amplification of FGFR2 in ~6% with concomitant elevation of mRNA of patients which correlated with PTPN11 (SHP2) mRNA expression. The broader context of this data is of value and could add a different patient demographic to other data on gastric cancer. However, there is no detail on patient stratification or prior therapeutic intervention.*

Thanks for pointing this out and we have added a table on patients' stratification such as age, gender and so on. Unfortunately, data on patients' prior therapeutic intervention weren't collected.

> *In SNU16 and KATOIII cells the combined therapy is shown to be effective and appears to be correlated with increased apoptotic effects (i.e. not immune response).*
>
> *Fig 2E suggests that the combined therapy in SNU16 cells is a little better than FGFR2-directed AZD457 inhibitor alone, particularly at the higher dose.*

> *The individual patient case study described via Fig 3 suggests efficacy of the combined therapy (at very high dosage), however, the cell biopsies only show reduced phosphorylation of ERK, but not AKT. This is at odds with the ex vivo cell-based assays. Thus, it is not clear how relevant this study is.*
>
> *The mouse xenograft study shows a convincing reduction in tumor mass/volume and clear reduction in pAKT, whilst pERK remains largely unaffected by the combined therapeutic approach. This is in conflict with the previous data which seems to show the opposite effect. In all, the impact of the dual therapy is unclear with respect to the two pathways mediated by ERK and AKT.*

Thank you for the comment. Previous researches have confirmed that both RAS/ERK and PI3K/AKT pathways are two important downstream signaling of FGFR2. In Fig 2E and F, we observed that in FGFR2-amplified cell lines dual blockade had significant inhibitory effects both on p-ERK and p-AKT, and the inhibitory effect on p-ERK is greater than that on p-AKT. Similarly, in Fig 3G, dual blockade mainly suppressed p-ERK, and slightly inhibited p-AKT and p-mTOR in cancer cells derived from the individual patient. Thus, in the two types in-vitro models, dual inhibition simultaneously inhibited both RAS/ERK and PI3K/AKT pathways, and primarily inhibited RAS/ERK pathway, which is not contradictory.



Author response image 11.



Author response image 12.



Author response image 13.

For the in-vivo animal model. Although dual inhibition had inhibitory effects on both pathways, it mainly suppressed p-AKT.

In both in vivo and in vitro models, combination therapy has a certain inhibitory effect on the RAS/ERK and PI3K/AKT pathways, but the emphasis on the two is not the same in vivo and in vitro. Considering the significant differences between in vivo and in vitro models, we believe that this difference in emphasis is understandable.



Author response image 14.

> *Finally, the authors demonstrate the impact of SHP2 on PD-1 expression and propose that the SHP099/AZD4547 combination therapy significantly induces the production of IFN-γ in CD8+ T cells. This part of the study is unconvincing and would benefit from the investigation of the tumor micro-environment to assess T cell infiltration.*

To investigate the tumor micro-environment to assess T cell infiltration, we have to establish our research model in immunocompetent mice. However, there is currently only one type of gastric cancer cell line derived from mice, MFC, which is not a cell line with FGFR2 amplification. We attempted to transfect FGFR2 amplification plasmids into MFC, but the transfection effect was poor, making it difficult to conduct in vivo animal experiments.

> ***Reviewer #3 (Public review):***
>
> *Strengths:*
>
> *The authors demonstrate that FGFR2 amplification positively correlates with PTPN11 in human gastric cancer samples, providing rationale for combination therapies. Furthermore, convincing data are provided demonstrating that targeting both FGFR and SHP2 is more effective than targeting either pathway alone using in vitro and in vivo models. The use of cells derived from a gastric cancer patient that progressed following treatment with an FGFR inhibitor is also a strength. The findings from this study support the conclusion that SHP2 inhibitors enhance the efficacy of FGFR-targeted therapies in cancer patients. This study also suggests that targeting SHP2 may also be an effective strategy for targeting cancers that are resistant to FGFR-targeted therapies.*
>
> *Weaknesses:*
>
> *The main caveat with these studies is the lack of an immune competent model with which to test the finding that this combination therapy enhances T cell cytotoxicity in vivo. Discussing this limitation within the context of these findings and future directions for this work, particularly since the combination therapy appears to work quite well without the presence of T cells in the environment, would be beneficial.*

Thank you for the great suggestion. To investigate the tumor micro-environment to assess T cell infiltration, we have to establish our research model in immunocompetent mice. However, there is currently only one type of gastric cancer cell line derived from mice, MFC, which is not a cell line with FGFR2 amplification. We attempted to transfect FGFR2 amplification plasmids into MFC, but the transfection effect was poor, making it difficult to conduct in vivo animal experiments.

> ***Recommendations for the authors:***

> ***Reviewer #1 (Recommendations for the authors):***
>
> *Minor points. The manuscript is poorly written and loaded with language errors.*

We sincerely thank you for your constructive suggestion and we are sorry for the mistake. We have polished the article and corrected these language errors.

> ***Reviewer #2 (Recommendations for the authors):***
>
> *In addition to the comments made in the Public Review the manuscript lacks detail on statistical analysis of experimental results.*

Thank you for your advice. In response to the feedback, we have supplemented detail on statistical analysis of experimental results in the “Methods” part.

> ***Reviewer #3 (Recommendations for the authors):***
>
> *There are numerous grammatical errors throughout, and incorrect wording is used in some places (such as "syngeneic mouse tumor model" rather than "xenograft tumor model", line 253). Careful proofreading and editing of this manuscript is recommended.*

Thank you for your suggestion. We have made corrections to the relevant content of the article.

> *AZD4547 is an FGFR-selective inhibitor and is not specific for FGFR2 as it also targets FGFR1 and FGFR3, this should be clarified in the text.*

Thank you for rasing this point. We have clarified that AZD4547 is an FGFR-selective inhibitor targeting FGFR1-3 in the “Introduction” part.

> *The specific FGFR inhibitor(s) used to treat the patient with FGFR2 amplification, are the authors able to provide this information?*

Thank you for raising this important issue. Indeed, due to the difficulty of small molecule drug development, the fastest clinical progress currently is in FGFR pan inhibitors. Recently, Relay Therapeutics has also developed a highly FGFR2-selective inhibitor, RLY-4008, in phase I/II clinical trials, but lacks preclinical research on gastric cancer.

> *Figure 2F: the p38 and p-p38 bands are cut off at the bottom*

We sincerely thank you for your thoughtful feedback. we have improved our experimental methods and retested the two p38 and p-p38 in Figure 2F by western blotting.



Author response image 15.

https://doi.org/10.7554/eLife.104060.2.sa0